Anebulo Pharmaceuticals Inc Stock Price, News & Analysis

Anebulo Pharmaceuticals (NASDAQ: ANEB) reported financial results for Q2 FY2022, highlighting a net loss of $1.1 million or $(0.05) per share, compared to a loss of $0.3 million or $(0.03) in Q2 FY2021. Operating expenses rose to $1.1 million from $0.3 million year-on-year. The company initiated a Phase 2 study of ANEB-001 for acute cannabinoid intoxication, expects topline results in H1 2022, and discussed clinical development with the FDA. The firm holds $18.0 million in cash as of December 31, 2021, down from $19.9 million in June 2021.

Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) will present a company overview at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. A webcast of the presentation will be available on-demand starting January 10, 2022, at 7:00 a.m. Eastern time on the Investors section of Anebulo's website. The company focuses on solutions for acute cannabinoid intoxication. Its lead candidate, ANEB-001, targets the negative effects of such intoxication and has shown promising results in clinical trials, demonstrating rapid absorption and tolerance.

Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) announced the appointment of Scott L. Anderson as Head of Investor Relations and Public Relations, effective immediately. Reporting to CFO Rex Merchant, Anderson will enhance the company's communication with shareholders and the investment community. With over 20 years of experience in investor relations at companies like Qualcomm and Actavis, he aims to grow Anebulo's shareholder base and improve transparency. CEO Daniel Schneeberger emphasized the timing is critical as the company prepares to report topline Phase 2 trial results in the first half of the year.

Anebulo Pharmaceuticals (NASDAQ: ANEB) has appointed Simon Allen as CEO and a Board member, effective February 1, 2022. He succeeds Daniel Schneeberger, MD, who has resigned. Allen previously served as Chief Business Officer at Ambrx Biopharma (NYSE: AMAM) and brings extensive leadership experience. Anebulo's primary focus is developing ANEB-001, aimed at treating acute cannabinoid intoxication, a growing concern with rising THC concentrations. The company anticipates reporting topline results from its Phase 2 trial in the first half of 2022.

Anebulo Pharmaceuticals (Nasdaq: ANEB) has initiated a Phase 2 clinical study for ANEB-001, targeting acute cannabinoid intoxication. The first patient has been dosed, with topline results expected in the first half of 2022. After a recent FDA pre-IND meeting, the company secured guidance on its regulatory approach, with plans to submit an IND in Q1 2022. The trial involves 60 patients, examining the efficacy of varying doses of ANEB-001 against THC-induced effects. Anebulo emphasizes the growing need for treatments, noting 1.7 million cannabinoid-related emergency visits in 2018.

Tenaya Therapeutics (NASDAQ: TNYA) announced two key appointments: Karah Parschauer to its Board of Directors and Joanna Auch as Senior VP of People and Culture. These appointments aim to strengthen Tenaya's leadership amid its transition to a public company with over 100 employees. CEO Faraz Ali highlighted that both individuals bring valuable experience and will enhance the company's capabilities in drug development for heart disease. Parschauer has extensive biopharmaceutical experience and previously held roles at Ultragenyx, while Auch has over 15 years in HR.

Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) announced its financial results for Q1 fiscal 2022, highlighting key business developments. The company obtained a U.S. patent for ANEB-001, which is set to treat acute cannabinoid overdose. Manufacturing of ANEB-001 capsules is complete for the upcoming Phase 2 clinical trial. The company has formed a Scientific Advisory Board to guide its clinical programs. Operating expenses surged to $1.55 million, and the net loss was $1.55 million or $(0.07) per share. As of September 30, 2021, cash reserves stood at approximately $19.2 million.

Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) announced that the U.S. Patent and Trademark Office has granted U.S. Patent No. 11,141,404, titled 'Formulations And Methods For Treating Acute Cannabinoid Overdose'. This patent covers ANEB-001, an investigational drug designed to treat acute cannabinoid overdose, with protection extending to 2040. CEO Daniel Schneeberger highlighted the urgent need for such treatments and confirmed a Phase 2 clinical study set for Q4 2023, with topline results expected in H1 2024.

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) announced its participation in the Benzinga Cannabis Capital Conference on October 14-15, 2021, in New York City. The management will present on October 15 at 3:25 p.m. Eastern Time and will engage in one-on-one meetings with investors throughout the event. Anebulo is focused on developing innovative treatments for acute cannabinoid intoxication and substance addiction, with its lead candidate, ANEB-001, demonstrating positive results in clinical trials. Investors can register for the event here.